Ewing's sarcoma

The Lancet Oncology

Volumn 11, Issue 2, 2010, Pages 184-192

  Balamuth, Naomi J ^a,b   Womer, Richard B ^a,b  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; BEVACIZUMAB; BUSULFAN; CARMUSTINE; CELECOXIB; CYCLOPHOSPHAMIDE; CYTARABINE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; FENRETINIDE; FIGITUMUMAB; GENE PRODUCT; IFOSFAMIDE; IMATINIB; IRINOTECAN; MAMMALIAN TARGET OF RAPAMYCIN; MELPHALAN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY IMC A12; PROTEIN TYROSINE KINASE; RAPAMYCIN; SOMATOMEDIN C; SORAFENIB; SUNITINIB; TEMOZOLOMIDE; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE;

ADOLESCENT DISEASE; ANGIOGENESIS; BONE TUMOR; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER SURVIVAL; CARDIOTOXICITY; CELL DEATH; CHILDHOOD CANCER; CLINICAL TRIAL; DIAGNOSTIC IMAGING; DRUG DOSE INCREASE; DRUG MEGADOSE; ENZYME INHIBITION; EUROPE; EWING SARCOMA; FUSION GENE; GENE FUSION; HUMAN; HYPERGLYCEMIA; KIDNEY CARCINOMA; METASTASIS; NONHUMAN; NORTH AMERICA; PRIORITY JOURNAL; REVIEW; SOFT TISSUE SARCOMA; SOLID TUMOR; TUMOR VASCULARIZATION;

ADOLESCENT; ANTINEOPLASTIC AGENTS; CHILD; FEMALE; HUMANS; MALE; NEOPLASM STAGING; SARCOMA, EWING'S;

EID: 75249086827     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(09)70286-4     Document Type: Review

References (75)

1. Rosen G., Wollner N., Tan C., et al. Disease-free survival in children with Ewing's sarcoma treated with radiation therapy and adjuvant four-drug sequential chemotherapy. Cancer 33 (1974) 384-393
2. Esiashvili N., Goodman M., and Marcus R. Changes in incidence and survival of Ewing sarcoma patients over the past 3 decades: Surveillance Epidemiology and End Results data. J Pediat Hematol Oncol 30 (2008) 425-430
3. Parkin D., Stiller C., and Nectoux J. International variations in the incidence of childhood bone tumors. Int J Cancer 53 (1993) 371-376
4. Grier H.E. The Ewing family of tumors: Ewing's sarcoma and primitive neuroectodermal tumors. Pediatr Clin North Am 44 (1997) 991-1004
5. Delattre O., Zucman J., Plougastel B., et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumors. Nature 359 (1992) 162-165
6. de Alava E., Kawai A., Healey J.H., et al. EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma. J Clin Oncol 16 (1998) 1248-1255
7. Kovar H., Le Deley M., Delattre O., et al. Impact of EWS-FLI1 fusion type on disease progression in Ewing's sarcoma: prospective results from the cooperative Euro-E.W.I.N.G.99 trial. Proc Annu Meet Am Assoc Cancer Res (2009) abstr 5680.
8. Schliermacher G., Peter M., Oberlin O., et al. Increased risk of systemic relapses associated with bone marrow micrometastasis and circulating tumor cells in localized Ewing tumor. J Clin Oncol 21 (2003) 85-91
9. Scotlandi K., Remondini D., Castellani G., et al. Overcoming resistance to conventional drugs in Ewing sarcoma and identification of molecular predictors of outcome. J Clin Oncol 27 (2009) 2209-2216
10. Ohali A., Avigad S., Zaizov R., et al. Prediction of high risk Ewing's sarcoma by gene expression profiling. Oncogene 23 (2004) 8997-9006
11. Schaefer K., Eisenacher M., Braun Y., et al. Microarray analysis of Ewing's sarcoma family of tumours reveals characteristic gene expression signatures associated with metastasis and resistance to chemotherapy. Eur J Cancer 44 (2008) 699-709
12. Meyer J., Nadel H., Marina N., et al. Imaging guidelines for children with Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group Bone Tumor Committee. Pediatr Blood Cancer 51 (2008) 163-170
13. Mazumdar A., Siegel M., Narra V., and Luchtman-Jones L. Whole-body fast inversion recovery MR imaging of small cell neoplasms in pediatric patients: a pilot study. Am J Roentgenology 179 (2002) 1261-1266
14. Volker T., Kenecke T., Steffen I., et al. Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial. J Clin Oncol 25 (2007) 5435-5441
15. Jaffe N., Paed D., Traggis D., Sallan S., and Cassady R. Improved outlook for Ewing's sarcoma with combination chemotherapy (vincristine, actinomycin D and cyclophosphamide) and radiation therapy. Cancer 38 (1976) 1925-1930
16. Nesbit M., Gehan E., Burgert E., et al. Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: a long-term follow-up of the First Intergroup Study. J Clin Oncol 8 (1990) 1664-1674
17. Burgert E., Nesbit M., Garnsey L., et al. Multimodal therapy for the management of nonpelvic, localized Ewing's sarcoma of bone: Intergroup Study IESS-II. J Clin Oncol 8 (1990) 1514-1524
18. Grier H., Krailo M., Tarbell N., et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroctodermal tumor of bone. N Engl J Med 348 (2003) 694-701
19. Granowetter L., Womer R., Devidas M., et al. Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children's Oncology Group study. J Clin Oncol 27 (2009) 2536-2541
20. Womer R., West D., Krailo M., Dickman P., and Pawel B. Chemotherapy intensification by interval compression in localized Ewing sarcoma family tumors (ESFT). Proc Am Soc Clin Oncol 26 (2008) abstr 10504.
21. Paulussen M., Ahrens S., Dunst J., et al. Localized Ewing tumor of bone: final results of the coopertive Ewing's Sarcoma Study CESS 86. J Clin Oncol 19 (2001) 1818-1829
22. Paulussen M., Craft A., Lewis I., et al. Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment-cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients. J Clin Oncol 26 (2008) 4385-4393
23. Juergens C., Weston C., Lewis I., et al. Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial. Pediatr Blood Cancer 47 (2006) 22-29
24. Saylors R., Stine S., Sullivan J., et al. Cyclophosphamide plus topotecan in children witth recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study. J Clin Oncol 19 (2001) 3463-3469
25. Hunold A., Weddeling N., Paulussen M., Ranft A., Liebscher C., and Jurgens H. Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors. Pediatr Blood Cancer 6 (2006) 795-800
26. Miser J., Goldsby R., Chen Z., et al. Treatment of metastatic Ewing sarcoma/primitive neuroectodermal tumor of bone: evaluation of increasing the dose intensity of chemotherapy-a report from the Children's Oncology Group. Pediatr Blood Cancer 49 (2007) 894-900
27. Meyers P., Krailo M., Ladany M., et al. High-dose melphalan, etoposide, total-body irradiation, and autologous stem-cell reconstitution as consoldation therapy for high-risk Ewing's sarcoma does not improve prognosis. J Clin Oncol 19 (2001) 2812-2820
28. Oberlin O., Rey A., Desfachelles A., et al. Impact of high-dose busulfan plus melphalan as consolidation in metastatic Ewing tumors: a study by the Societe Francaise des Cancers de l'Enfant. J Clin Oncol 24 (2006) 3997-4002
29. Burdach S., van Kaick B., Laws H., et al. Allogeneic and autologous stem-cell transplantation in advanced Ewing tumors: an update after long-term follow-up from two centers of the Europen Intergroup Study EICESS. Ann Oncol 11 (2000) 1451-1462
30. Burdach S., Meyer-Bahlburg A., Laws H., et al. High-dose therapy for patients with primary multifocal and early relapsed Ewing's tumors: results of two consecutive regimens assessing the role of total-body irradiation. J Clin Oncol 21 (2003) 3072-3078
31. Bacci G., Ferrari S., Longhi A., et al. Therapy and survival after recurrence of Ewing's tumors: the Rizzoli experience in 195 patients treated with adjuvant and neoadjuvant chemotherapy from 1979 to 1997. Ann Oncol 14 (2003) 1654-1659
32. Leavey P.J., Mascarenhas L., Marina N., et al. Prognostic factors for patients with Ewing sarcoma (EWS) at first recurrence following multi-modality therapy: a report from the Children's Oncology Group. Pediatr Blood Cancer 51 (2008) 334-338
33. Barker L., Pendergrass T.W., Sanders J., and Hawkins D. Survival after recurrence of Ewing's sarcoma family of tumors. J Clin Oncol 23 (2005) 4354-4362
34. Schuck A., Ahrens S., Paulussen M., et al. Local therapy in localized Ewing tumors: results of 1058 patients treated in the CESS 81, CESS 86, and EICESS 92 trials. Int J Rad Oncol Biol Phys 55 (2003) 168-177
35. Yock T., Krailo M., Fryer C.J., et al. Local control in pelvic Ewing sarcoma: analysis from INT-0091-a report from the Children's Oncology Group. J Clin Oncol 24 (2006) 3838-3843
36. Donati D., Yin J., Di Bella C., et al. Local and distant control in non-metastatic pelvic Ewing's sarcoma patients. J Surg Oncol 96 (2007) 19-25
37. Riggi N., Suva M., Suva D., et al. EWS-FLI-1 expression triggers a Ewing's sarcoma initiation program in primary human mensenchymal stem cells. Cancer Res 68 (2008) 2176-2185
38. Kovar H., Aryee D., Jug G., et al. EWS/FLI-1 antagonists induce growth inhibition of Ewing tumor cells in vitro. Cell Growth Differ 7 (1996) 429-437
39. Chansky H., Barahmand-Pour F., Mei Q., et al. Targeting of EWS/FLI-1 by RNA interference attenuates the tumor phenotype of Ewing's sarcoma cells in vitro. J Orthoped Res 22 (2004) 910-917
40. DuBois S.G., Krailo M.D., Lessnick S.L., et al. Phase II study of intermediate-dose cytarabine in patients with relapsed or refractory Ewing sarcoma: a report from the Children's Oncology Group. Pediatr Blood Cancer 52 (2009) 324-327
41. Erkizan H., Kong Y., Merchant M., et al. A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma. Nat Med 15 (2009) 750-756
42. Larsson O., Girnita A., and Girnita L. Role of insulin-like growth factor 1 receptor signalling in cancer. Br J Cancer 92 (2005) 2097-2101
43. Scotlandi K., Benini S., Sarti M., et al. Insulin-like growth factor I receptor-mediated circuit in Ewing's sarcoma/peripheral neuroectodermal tumor: a possible therapeutic target. Cancer Res 56 (1996) 4570-4574
44. Prieur A., Tirode F., Cohen P., and Delattre O. EWS/FLI1 silencing and gene profiling of Ewing cells reveal downsream oncogenic pathways and a crucial role for repression on insulin-like growth factor binding protein 3. Mol Cell Biol 24 (2004) 7275-7283
45. Benini S., Zuntini M., Manara M., et al. Insulin-like growth factor binding protein 3 as an anticancer molecule in Ewing's sarcoma. Int J Cancer 119 (2006) 1039-1046
46. Higano C., Yu E., and Whiting S. A phase I, first in man study of weekly IMC-A12, a fully human insulin like growth factor-I receptor IgG1 monoclonal antibody, in patients with advanced solid tumors. Proc Am Soc Clin Oncol 25 (2007) Abstr 269.
47. Olmos D., Postel-Vinay P., Molife L.R., et al. Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. Lancet Oncol 11 (2010) 129-135
48. Benini S., Manara M., Baldini N., et al. Inhibition of insulin-like growth factor I receptor increases the antitumor activity of doxorubicin and vincristine against Ewing's sarcoma cells. Clin Cancer Res 7 (2001) 1790-1797
49. Manara M., Landuzzi L., Nanni P., et al. Preclinical in vivo study of new insulin-like growth factor-1 receptor-specific inhibitor in Ewing's sarcoma. Clin Cancer Res 13 (2007) 1322-1330
50. Ricotti E., Fagioli F., Garelli E., et al. c-kit is expressed in soft tissue sarcoma of neuroectodermic origin and its ligand prevents apoptosis of neoplastic cells. Blood 91 (1998) 2397-2405
51. Bond M., Bernstein M., Pappo A., et al. A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer 50 (2008) 254-258
52. Rodenhuis S. Ras and human tumors. Semin Cancer Biol 3 (1992) 241-247
53. Mercer K., and Pritchard C. Raf proteins and cancer: B-Raf is identified as a mutational target. Biochim Biophys Acta 1653 (2003) 25-40
54. Guan H., Zhou Z., Gallick G., et al. Targeting Lyn inhibits tumor growth and metastasis in Ewing's sarcoma. Mol Cancer Ther 7 (2008) 1807-1816
55. Hidalgo M., and Rowinsky E. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene 19 (2000) 6680-6686
56. Mateo-Lonzano S., Tirado O., and Notario V. Rapamycin induces the fusion-type independent downregulation of the EWS/FLI-1 proteins and inhibits Ewing's sarcoma cell proliferation. Oncogene 22 (2003) 9282-9287
57. Mateo-Lonzano S., Gokhale P., Soldatenkov V., Dritschilo A., Tirado O., and Notario V. Combined transcriptional and translational targeting of EWS/FLI-1 in Ewing's sarcoma. Clin Cancer Res 12 (2006) 6781-6790
58. Huang H., Illei P., Zhao Z., et al. Ewing sarcomas with p53 mutation or p16/ARF homozygous deletion: a highly lethal subset associated with poor chemoresponse. J Clin Oncol 23 (2005) 548-558
59. Dey A., Verma C., and Lane D. Updates on p53: modulation of p53 degradation as a therapeutic approach. Br J Cancer 98 (2008) 4-8
60. LeFranc F., Facchini V., and Kiss R. Proautophagic drugs: a novel means to combat apoptosis-resistant cancers, with a special emphasis on glioblastomas. The Oncologist 12 (2007) 1395-1403
61. Sohn H., Choi E., Kim S., et al. Engagement of CD99 induces apoptosis through a calcineurin-independent pathway in Ewing's sarcoma cells. Am J Pathol 153 (1998) 1937-1945
62. Scotlandi K., Baldini N., Cerisano V., et al. CD99 engagement: an effective therapeutic strategy for Ewing tumors. Cancer Res 60 (2000) 5134-5142
63. Scotlandi K., Perdichizzi S., Bernard G., et al. Targeting CD99 in association with doxorubicin: an effective combined treatment for Ewing's sarcoma. Eur J Cancer 42 (2006) 91-96
64. Matthay K., Villablanca J., Seeger R., et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation and 13-cis-retinoic acid. N Engl J Med 341 (1999) 1165-1173
65. Fang J., Chen S., Tong J., Wang Z., Chen G., and Chen Z. Treatment of acute promyelocytic leukemia with ATRA as As2O3: a model of molecular target-based cancer therapy. Cancer Biol Ther 1 (2002) 614-620
66. Burchill S., Berry P., Bradbury F., and Lewis I. Contrasting levels of p21ras activation and expression of neurofibromin in peripheral primitive neuroectodermal tumor and neuroblastoma cells, and their response to retinoic acid. J Neurol Sci 157 (1998) 129-137
67. Myatt S., and Burchill S. The sensitivity of the Ewing's sarcoma family of tumours to fenretinide-induced cell death is increased by EWS-Fli1-dependent modulation of p38(MAPK) activity. Oncogene 27 (2008) 985-996
68. Myatt S., Redfern C., and Burchill S. p38MAPK-Dependent sensitivity of Ewing's sarcoma family of tumors to fenretinide-induced cell death. Clin Cancer Res 11 (2005) 3136-3148
69. Maurer B., Kalous O., Yesair D., et al. Improved oral delivery of N-(4-hydroxyphenyl)retinamide with a novel LYM-X-SORB organized lipid complex. Clin Cancer Res 13 (2007) 3079-3086
70. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other diseases. Nat Med 1 (1995) 27-31
71. Dalal S., Berry A., Cullinane C., et al. Vascular endothelial growth factor: a therapeutic target for tumors of the Ewing's sarcoma family. Clin Cancer Res 11 (2005) 2364-2378
72. Kreuter M., Paulussen M., Boeckeler J., et al. Clinical significance of vascular endothelial growth factor-A expression in Ewing's sarcoma. Eur J Cancer 42 (2006) 1904-1911
73. D'Adamo D., Anderson S., Albritton K., et al. Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. J Clin Oncol 23 (2005) 7135-7142
74. Kieran M., Turner C., Rubin J., et al. A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer. J Pediatr Hematol Oncol 27 (2005) 573-581
75. Sposto R., and Stram D.O. A strategic view of randomized trial design in low-incidence pediatric cancer. Stat Med 18 (1999) 1183-1197